Top healthcare mergers and acquisitions in April 2026
Every verified merger and acquisition in the healthcare sector in this period, ranked by disclosed value. Updated every morning.
We tracked 17 deals in the healthcare sector in April 2026, 14 of them with a disclosed value, worth $29.3bn in total. The largest was Sun Pharmaceutical Industries Ltd's $11.8bn deal for Organon & Co., ahead of Eli Lilly and Company and Kelonia Therapeutics, Inc. at $3.3bn.
Top healthcare mergers and acquisitions in April 2026
- 126 AprSun Pharmaceutical Industries Ltd → Organon & Co.Sun Pharma agrees US$11.75bn takeover of OrganonHealthcare / PharmaceuticalsIn review$11.8bn
- 220 AprEli Lilly and Company → Kelonia Therapeutics, Inc.Lilly agrees up-to-US$7bn deal for in vivo CAR-T developer KeloniaHealthcare / BiotechCompleted$3.3bn
- 37 AprGilead Sciences, Inc. → Tubulis GmbHGilead agrees up to US$5bn deal for TubulisHealthcare / BiotechCompleted$3.2bn
- 46 AprNeurocrine Biosciences, Inc. → Soleno Therapeutics, Inc.Neurocrine agrees US$2.9bn takeover of Soleno TherapeuticsHealthcare / BiotechCompleted$2.9bn
- 529 AprChiesi Farmaceutici S.p.A. → KalVista Pharmaceuticals, Inc.Chiesi agrees US$1.9bn takeover of KalVistaHealthcare / BiotechCompleted$1.9bn
- 614 AprAmerican Industrial Partners → Avanos Medical, Inc.American Industrial Partners agrees US$1.27bn take-private of Avanos MedicalHealthcare / Medical devicesCompleted$1.3bn
- 727 AprAstorg (Astorg VIII) → Thermo Fisher Scientific microbiology business (Oxoid and Remel)Astorg buys Thermo Fisher's microbiology business for US$1.075bnHealthcare / DiagnosticsCompleted$1.1bn
- 829 AprTeva Pharmaceutical Industries Ltd → Emalex BiosciencesTeva agrees up-to-US$900m deal for Tourette drug developer EmalexHealthcare / BiotechCompleted$900m
- 922 AprAmneal Pharmaceuticals, Inc. → Kashiv BioSciences, LLCAmneal agrees up-to-US$1.1bn deal for biosimilars maker KashivHealthcare / BiosimilarsCompleted$750m
- 1027 AprLigand Pharmaceuticals Incorporated → XOMA Royalty CorporationLigand agrees US$739m takeover of XOMA RoyaltyHealthcare / Biopharma royaltiesCompleted$739m
- 1117 AprUCB SA → Neurona Therapeutics Inc.UCB agrees up-to-US$1.15bn deal for epilepsy cell therapy developer NeuronaHealthcare / BiotechCompleted$650m
- 1213 AprRevenio Group Oyj → Visionix (LT International SAS)Revenio agrees €290m deal for VisionixHealthcare / Ophthalmic diagnosticsCompleted$339m
- 1316 AprCharterhouse Capital Partners (CCP Paw 2) → Animalcare Group plcCharterhouse agrees £235m take-private of veterinary group AnimalcareHealthcare / Veterinary pharmaceuticalsCompleted$320m
- 1414 AprEverstone Capital → Apothecon Group (Apothecon Pharmaceuticals and Navinta)Everstone invests US$270m in Indian generics maker ApotheconHealthcare / Generic pharmaceuticalsAgreed$270m
- 1527 AprEli Lilly and Company → Ajax Therapeutics, Inc.Lilly agrees up-to-US$2.3bn deal for JAK2 specialist AjaxHealthcare / BiotechCompletedUndisclosed
- 1624 AprJohnson & Johnson → Atraverse Medical, Inc.J&J agrees to buy left-heart access specialist Atraverse MedicalHealthcare / Medical devicesCompletedUndisclosed
- 1723 AprInventurus Knowledge Solutions (IKS Health) → TruBridge, Inc.IKS Health agrees to buy rural hospital software provider TruBridgeHealthcare / Health ITCompletedUndisclosed